Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Ex Vivo Culture of Cells Derived From Circulating Tumour Cell Xenograft to support Small Cell Lung Cancer Research and Experimental Therapeutics.

Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, Gorgoulis VG, Miller C, Blackhall F, Helleday T, Dive C.

Br J Pharmacol. 2018 Nov 14. doi: 10.1111/bph.14542. [Epub ahead of print]

PMID:
30427531
2.

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.

Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C.

Nat Commun. 2018 Nov 7;9(1):4672. doi: 10.1038/s41467-018-07174-1.

3.

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Blackhall F, Frese KK, Simpson K, Kilgour E, Brady G, Dive C.

Lancet Oncol. 2018 Sep;19(9):e470-e481. doi: 10.1016/S1470-2045(18)30455-8. Review.

PMID:
30191851
4.

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-18-1569. [Epub ahead of print]

PMID:
30082476
5.

Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.

Torres-Ayuso P, Sahoo S, Ashton G, An E, Simms N, Galvin M, Leong HS, Frese KK, Simpson K, Cook N, Hughes A, Miller CJ, Marais R, Dive C, Krebs MG, Brognard J.

NPJ Genom Med. 2018 Jun 20;3:15. doi: 10.1038/s41525-018-0055-6. eCollection 2018.

6.

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.

Lallo A, Frese KK, Morrow CJ, Sloane R, Gulati S, Schenk MW, Trapani F, Simms N, Galvin M, Brown S, Hodgkinson CL, Priest L, Hughes A, Lai Z, Cadogan E, Khandelwal G, Simpson KL, Miller C, Blackhall F, O'Connor MJ, Dive C.

Clin Cancer Res. 2018 Oct 15;24(20):5153-5164. doi: 10.1158/1078-0432.CCR-17-2805. Epub 2018 Jun 25.

PMID:
29941481
7.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.

PMID:
29925934
8.

Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging.

Salem A, Mistry H, Backen A, Hodgson C, Koh P, Dean E, Priest L, Haslett K, Trigonis I, Jackson A, Asselin MC, Dive C, Renehan A, Faivre-Finn C, Blackhall F.

Clin Lung Cancer. 2018 May;19(3):239-248.e7. doi: 10.1016/j.cllc.2017.12.002. Epub 2017 Dec 11.

9.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
10.

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.

Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A.

Clin Colorectal Cancer. 2018 Mar;17(1):80-83. doi: 10.1016/j.clcc.2017.10.017. Epub 2017 Nov 1.

PMID:
29195807
11.

Targeting DNA damage in SCLC.

Foy V, Schenk MW, Baker K, Gomes F, Lallo A, Frese KK, Forster M, Dive C, Blackhall F.

Lung Cancer. 2017 Dec;114:12-22. doi: 10.1016/j.lungcan.2017.10.006. Epub 2017 Oct 16. Review.

PMID:
29173760
12.

PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways.

Naidu S, Shi L, Magee P, Middleton JD, Laganá A, Sahoo S, Leong HS, Galvin M, Frese K, Dive C, Guzzardo V, Fassan M, Garofalo M.

Sci Rep. 2017 Nov 13;7(1):15441. doi: 10.1038/s41598-017-14843-6.

13.

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F.

Transl Lung Cancer Res. 2017 Aug;6(4):409-417. doi: 10.21037/tlcr.2017.07.05. Review.

14.

Circulating tumor cells and CDX models as a tool for preclinical drug development.

Lallo A, Schenk MW, Frese KK, Blackhall F, Dive C.

Transl Lung Cancer Res. 2017 Aug;6(4):397-408. doi: 10.21037/tlcr.2017.08.01. Review.

15.

Spotlight on circulating tumour cells.

Blackhall F, Dive C.

Transl Lung Cancer Res. 2017 Aug;6(4):396. doi: 10.21037/tlcr.2017.08.05. No abstract available.

16.

Progress and prospects of early detection in lung cancer.

Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C.

Open Biol. 2017 Sep;7(9). pii: 170070. doi: 10.1098/rsob.170070. Review.

17.

Molecular analysis of single circulating tumour cells following long-term storage of clinical samples.

Mesquita B, Rothwell DG, Burt DJ, Chemi F, Fernandez-Gutierrez F, Slane-Tan D, Antonello J, Carter M, Carter L, Parry M, Franklin L, Marais R, Blackhall F, Dive C, Brady G.

Mol Oncol. 2017 Dec;11(12):1687-1697. doi: 10.1002/1878-0261.12113. Epub 2017 Oct 24.

18.

twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis.

Chiu A, Ayub M, Dive C, Brady G, Miller CJ.

Bioinformatics. 2017 Sep 1;33(17):2743-2745. doi: 10.1093/bioinformatics/btx308.

19.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

20.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

21.

Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models.

Khandelwal G, Girotti MR, Smowton C, Taylor S, Wirth C, Dynowski M, Frese KK, Brady G, Dive C, Marais R, Miller C.

Mol Cancer Res. 2017 Aug;15(8):1012-1016. doi: 10.1158/1541-7786.MCR-16-0431. Epub 2017 Apr 25.

22.

SnapShot: Circulating Tumor Cells.

Dive C, Brady G.

Cell. 2017 Mar 23;169(1):176. doi: 10.1016/j.cell.2017.03.017. No abstract available.

23.

SnapShot: Circulating Tumor Cells.

Dive C, Brady G.

Cell. 2017 Feb 9;168(4):742-742.e1. doi: 10.1016/j.cell.2017.01.026. Erratum in: Cell. 2017 Mar 23;169(1):176.

24.

Cancer Moonshot Connecting International Liquid Biopsy Efforts Through Academic Partnership.

Dive C, Shishido SN, Kuhn P.

Clin Pharmacol Ther. 2017 May;101(5):622-624. doi: 10.1002/cpt.657. Epub 2017 Mar 22. Review.

PMID:
28182274
25.

Novel risk models for early detection and screening of ovarian cancer.

Russell MR, D'Amato A, Graham C, Crosbie EJ, Gentry-Maharaj A, Ryan A, Kalsi JK, Fourkala EO, Dive C, Walker M, Whetton AD, Menon U, Jacobs I, Graham RL.

Oncotarget. 2017 Jan 3;8(1):785-797. doi: 10.18632/oncotarget.13648.

26.

Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.

Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, Li Y, Burt DJ, Antonello J, Morrow CJ, Hodgkinson CL, Morris K, Priest L, Carter M, Miller C, Hughes A, Blackhall F, Dive C, Brady G.

Nat Med. 2017 Jan;23(1):114-119. doi: 10.1038/nm.4239. Epub 2016 Nov 21.

PMID:
27869802
27.

Vasculogenic mimicry in small cell lung cancer.

Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, Leong HS, Chester CP, Simms N, Polanski R, Nonaka D, Priest L, Fusi A, Carlsson F, Carlsson A, Hendrix MJ, Seftor RE, Seftor EA, Rothwell DG, Hughes A, Hicks J, Miller C, Kuhn P, Brady G, Simpson KL, Blackhall FH, Dive C.

Nat Commun. 2016 Nov 9;7:13322. doi: 10.1038/ncomms13322.

28.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

29.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R.

Ann Oncol. 2016 Oct;27(10):1959-65. doi: 10.1093/annonc/mdw278. Epub 2016 Aug 8.

30.

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC.

Crosbie PA, Shah R, Krysiak P, Zhou C, Morris K, Tugwood J, Booton R, Blackhall F, Dive C.

J Thorac Oncol. 2016 Oct;11(10):1793-7. doi: 10.1016/j.jtho.2016.06.017. Epub 2016 Jul 25.

31.

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

Jahchan NS, Lim JS, Bola B, Morris K, Seitz G, Tran KQ, Xu L, Trapani F, Morrow CJ, Cristea S, Coles GL, Yang D, Vaka D, Kareta MS, George J, Mazur PK, Nguyen T, Anderson WC, Dylla SJ, Blackhall F, Peifer M, Dive C, Sage J.

Cell Rep. 2016 Jul 19;16(3):644-56. doi: 10.1016/j.celrep.2016.06.021. Epub 2016 Jun 30.

32.

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC.

Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28.

33.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

34.

Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.

Potter DS, Galvin M, Brown S, Lallo A, Hodgkinson CL, Blackhall F, Morrow CJ, Dive C.

Mol Cancer Ther. 2016 Jun;15(6):1248-60. doi: 10.1158/1535-7163.MCT-15-0885. Epub 2016 Mar 29.

35.

PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.

Kirwan CC, Bundred NJ, Castle J, Clarke R, Dive C, Morris J, Holcombe C, Harvey JR.

Thromb Res. 2016 Apr;140 Suppl 1:S189-90. doi: 10.1016/S0049-3848(16)30169-4. Epub 2016 Apr 8.

PMID:
27161723
36.

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F.

Ann Oncol. 2016 Aug;27(8):1443-8. doi: 10.1093/annonc/mdw192. Epub 2016 May 3.

PMID:
27143638
37.

Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.

Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL, Williamson S, Wirth C, Simms N, Frankliln L, Frese KK, Rothwell DG, Nonaka D, Miller CJ, Brady G, Blackhall FH, Dive C.

Ann Oncol. 2016 Jun;27(6):1155-60. doi: 10.1093/annonc/mdw122. Epub 2016 Mar 24.

38.

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.

Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW.

Br J Haematol. 2016 Apr;173(2):274-82. doi: 10.1111/bjh.13954. Epub 2016 Feb 5.

PMID:
26849853
39.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

40.

Protein Z: A putative novel biomarker for early detection of ovarian cancer.

Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala EO, Whetton AD, Menon U, Jacobs I, Graham RL.

Int J Cancer. 2016 Jun 15;138(12):2984-92. doi: 10.1002/ijc.30020. Epub 2016 Feb 19.

41.

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J.

EMBO Mol Med. 2016 Feb 1;8(2):105-16. doi: 10.15252/emmm.201505456.

42.

Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response.

Memon D, Dawson K, Smowton CS, Xing W, Dive C, Miller CJ.

NPJ Genom Med. 2016;1:16020. doi: 10.1038/npjgenmed.2016.20. Epub 2016 Jul 20.

43.

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, Baenke F, Pedersen M, Rogan J, Swan J, Smith M, Fusi A, Oudit D, Dhomen N, Brady G, Lorigan P, Dive C, Marais R.

Cancer Discov. 2016 Mar;6(3):286-99. doi: 10.1158/2159-8290.CD-15-1336. Epub 2015 Dec 29.

44.

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man.

Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, Hodgkinson CL, Morrow CJ, Smith N, Aung K, Valle J, Carter L, Blackhall F, Dive C, Brady G.

Mol Oncol. 2016 Feb;10(2):282-91. doi: 10.1016/j.molonc.2015.10.004. Epub 2015 Oct 28.

45.

Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample.

Rothwell DG, Smith N, Morris D, Leong HS, Li Y, Hollebecque A, Ayub M, Carter L, Antonello J, Franklin L, Miller C, Blackhall F, Dive C, Brady G.

Mol Oncol. 2016 Apr;10(4):566-74. doi: 10.1016/j.molonc.2015.11.006. Epub 2015 Nov 19.

46.

Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer.

Chudziak J, Burt DJ, Mohan S, Rothwell DG, Mesquita B, Antonello J, Dalby S, Ayub M, Priest L, Carter L, Krebs MG, Blackhall F, Dive C, Brady G.

Analyst. 2016 Jan 21;141(2):669-78. doi: 10.1039/c5an02156a.

PMID:
26605519
47.

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.

Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M, Hudson E, Reed N, Flubacher M, Jankowska P, Powell M, Dive C, West CML, Paul J.

Lancet Oncol. 2015 Nov;16(15):1515-1524. doi: 10.1016/S1470-2045(15)00220-X. Epub 2015 Oct 22.

48.

Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.

Walker MJ, Zhou C, Backen A, Pernemalm M, Williamson AJ, Priest LJ, Koh P, Faivre-Finn C, Blackhall FH, Dive C, Whetton AD.

EBioMedicine. 2015 Jun 19;2(8):841-50. doi: 10.1016/j.ebiom.2015.06.013. eCollection 2015 Aug.

49.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

50.

Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.

Kershaw S, Cummings J, Morris K, Tugwood J, Dive C.

BMC Cancer. 2015 May 10;15:387. doi: 10.1186/s12885-015-1382-y.

Supplemental Content

Support Center